G1T38

DRUG2 trials

Sponsors

G1 Therapeutics, Inc.

Conditions

Breast CancerBreast NeoplasmCarcinoma, Ductal, BreastCarcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer

Phase 1

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

G1 Therapeutics, Inc.Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Breast

Start: 2017-01-31End: 2023-10-31Target: 102Updated: 2023-02-15

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

CompletedNCT03455829

G1 Therapeutics, Inc.Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer

Start: 2018-03-29End: 2022-02-14Updated: 2023-05-06

Related Papers

Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients

Clinical and Translational Medicine2020-08-0129 citations

Abstract P1-19-17: Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer

Cancer Research2020-02-156 citations

Abstract 4415: CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer

Cancer Research2019-07-013 citations

Abstract 4415: CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer

Molecular and Cellular Biology / Genetics2019-07-011 citations

G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary phase 1b results.

Journal of Clinical Oncology2018-05-201 citations